John Mendlein, Director at FATE THERAPEUTICS INC (FATE), bought 16,667 shares at $6.00 ($100K) on 2013-10-04, disclosed to the SEC on 2013-10-07.
Open-market purchase of $100k FATE by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |
| FATE | SELL | 2022-03-11 | $2.2M | — | Filing → |
| LIFE | BUY | 2018-12-26 | $102K | — | Filing → |
| LIFE | BUY | 2017-09-05 | $200K | — | Filing → |